S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:ARDX - Ardelyx Stock Price, Forecast & News

$5.77
+0.18 (+3.22 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$5.51
Now: $5.77
$5.86
50-Day Range
$4.35
MA: $6.60
$8.79
52-Week Range
$2.10
Now: $5.77
$8.81
Volume684,807 shs
Average Volume854,042 shs
Market Capitalization$379.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Read More
Ardelyx logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.28 million
Book Value$2.84 per share

Profitability

Net Income$-94,940,000.00

Miscellaneous

Employees86
Market Cap$379.67 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.


Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

How has Ardelyx's stock been impacted by COVID-19 (Coronavirus)?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARDX shares have decreased by 3.5% and is now trading at $5.77. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ardelyx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ardelyx.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Ardelyx.

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.37) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.37). The biopharmaceutical company had revenue of $3.01 million for the quarter. View Ardelyx's earnings history.

What price target have analysts set for ARDX?

5 brokers have issued 12-month target prices for Ardelyx's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's share price to reach $12.00 in the next year. This suggests a possible upside of 108.0% from the stock's current price. View analysts' price targets for Ardelyx.

Has Ardelyx been receiving favorable news coverage?

Media coverage about ARDX stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ardelyx earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View the latest news aboutArdelyx.

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 54)
  • Mr. David Rosenbaum, Chief Devel. Officer (Age 58)
  • Mr. Mark E. Kaufmann, CFO & Treasurer (Age 51)
  • Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 56)
  • Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 65)

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional investors include NEA Management Company LLC (24.52%), RA Capital Management L.P. (8.14%), Renaissance Technologies LLC (3.74%), Marshall Wace LLP (1.74%), State Street Corp (1.35%) and Geode Capital Management LLC (1.26%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab and Scott D Sandell. View institutional ownership trends for Ardelyx.

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, State Street Corp, Jacobs Levy Equity Management Inc., Tower Research Capital LLC TRC, Blair William & Co. IL, and Citigroup Inc.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, and Michael Raab. View insider buying and selling activity for Ardelyx.

Which institutional investors are buying Ardelyx stock?

ARDX stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Marshall Wace LLP, NEA Management Company LLC, Ikarian Capital LLC, J. Goldman & Co LP, Bailard Inc., FMR LLC, and Goldman Sachs Group Inc.. View insider buying and selling activity for Ardelyx.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $5.77.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $379.67 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 86 workers across the globe. View additional information about Ardelyx.

What is Ardelyx's official website?

The official website for Ardelyx is http://www.ardelyx.com/.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]


MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  466 (Vote Outperform)
Underperform Votes:  412 (Vote Underperform)
Total Votes:  878
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel